Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;23(1):1-6.
doi: 10.1091/mbc.E10-04-0335.

The proliferation rate paradox in antimitotic chemotherapy

Timothy J Mitchison  1
Affiliations

The proliferation rate paradox in antimitotic chemotherapy

Timothy J Mitchison. Mol Biol Cell. 2012 Jan.

Abstract

Cytotoxic cancer chemotherapy drugs are believed to gain selectivity by targeting cells that proliferate rapidly. However, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a drug that only kills dividing cells could promote tumor regression. Four potential solutions to this "proliferation rate paradox" are discussed for the microtubule-stabilizing drug paclitaxel: drug retention in tumors, killing of quiescent cells, targeting of noncancer cells in the tumor, and bystander effects. Testing these potential mechanisms of drug action will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemotherapy more generally.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Chromatin morphology reports responses of dividing cancer cells to paclitaxel in a tumor. HT1080 human cancer cells expressing histone H2B-GFP were grown as xenograft tumors in window chambers in nude mice, treated with paclitaxel, and imaged by laser confocal microscopy. Cells that divided in drug proceeded from mitotic arrest to multiple micronuclei and apoptosis. Next to far right and far right, sequential images of the same cell from a movie. (From Orth et al., 2011.)
FIGURE 2:
FIGURE 2:
Potential actions of paclitaxel on tumor cells. Green arrows show cell cycle transitions. Red arrows show the only well-characterized drug action—killing cancer cells that enter mitosis. Blue arrows show hypothetical mechanisms for killing quiescent cancer cells that would provide solutions to the proliferation rate paradox.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Giunchi DC, Vio A, Saragoni A, Silvestrini R. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat. 1997;43:7–14. - PubMed
    1. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162. - PMC - PubMed
    1. Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JH, Holdaway KM, van Zijl P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer. 1995;31A:230–237. - PubMed
    1. Berenbaum MC. In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep. 1972;56:563–71. - PubMed
    1. Blagosklonny MV, Demidenko ZN, Giovino M, Szynal C, Donskoy E, Herrmann RA, Barry JJ, Whalen AM. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle. 2006;5:1574–1579. - PubMed

Publication types

Substances

LinkOut - more resources